Skip to main content
海昇药业 logo

海昇药业 — Investor Relations & Filings

Ticker · 920656 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 271 across all filing types
Latest filing 2024-04-25 Interim / Quarterly Rep…
Country CN China
Listing Beijing Stock Exchange 920656

About 海昇药业

https://www.zcpc.net/

Zhejiang Haisheng Pharmaceutical Co., Ltd. specializes in the research, development, production, and sale of active pharmaceutical ingredients (APIs) and pharmaceutical intermediates. The company's core product portfolio includes antipyretic and analgesic medications, cardiovascular agents, and various specialty chemical intermediates. It is recognized as a major global supplier of Naproxen and Naproxen Sodium. Haisheng Pharmaceutical maintains rigorous quality control systems compliant with international standards, including Good Manufacturing Practice (GMP) certifications. The company serves a diverse global clientele, providing high-purity chemical components essential for finished dosage form manufacturing. Its technical expertise focuses on chemical synthesis and process optimization to ensure stable supply chains for the pharmaceutical industry.

Recent filings

Filing Released Lang Actions
2024年一季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "2024 年第一季度报告" which translates to "2024 First Quarter Report." It contains detailed financial statements including balance sheet, income statement, and cash flow statement for the period ending March 31, 2024. The report includes comparative figures for the previous year, management assurances about the accuracy of the report, and notes that the report is unaudited. The content is comprehensive and covers a period shorter than a full fiscal year, consistent with an interim or quarterly report. There is no indication that this is merely an announcement or a certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q1 2024
2024-04-25 Chinese
第三届监事会第十四次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Zhejiang Haisheng Pharmaceutical Co., Ltd. It details the meeting date, attendance, and the approval of various proposals including the 2023 annual report, financial statements, budget, dividend plan, audit firm appointment, and the 2024 first quarter report. The document references that the actual reports and announcements are published separately on the Beijing Stock Exchange information disclosure website with specific announcement numbers. The document itself does not contain the full annual report or financial statements but is a formal announcement of the Supervisory Board meeting resolutions. This fits the category of a Regulatory Filing (RNS) as it is a formal regulatory announcement of meeting resolutions and approvals, not the full reports themselves. The document length is under 5,000 characters and it refers to other documents for the full reports, so it is not the reports themselves but an announcement of resolutions.
2024-04-25 Chinese
关于2023年度会计师事务所履职情况评估报告
Audit Report / Information Classification · 95% confidence The document is titled as a report on the evaluation of the accounting firm's performance for the 2023 fiscal year audit. It details the auditor's qualifications, the audit process, and the company's assessment of the auditor's independence and performance. It does not contain the full annual financial statements or detailed financial data but rather an evaluation of the auditor's work. This fits the description of an Audit Report / Information (AR) as it is a standalone audit-related report focusing on the auditor's performance and compliance with auditing standards, not the full annual report itself. The document length is short (1459 characters), but it is a substantive report, not merely an announcement or certification, so it is not RPA or RNS. Therefore, the correct classification is AR with high confidence. FY 2023
2024-04-25 Chinese
关于董事会审计委员会对会计师事务所履行监督职责情况报告
Audit Report / Information Classification · 95% confidence The document is a report from the Board Audit Committee regarding the supervision of the accounting firm (auditor) for the fiscal year 2023. It details the auditor's qualifications, the process of appointment, and the committee's evaluation of the auditor's performance and independence. The document does not contain the audit report itself or detailed financial statements but rather a supervisory report on the auditor's conduct and performance. This fits the definition of an Audit Report / Information (AR) filing, which includes standalone audit reports and information about the auditor's role and oversight, excluding the full annual report. The document length is short (1599 characters), but it is substantive and not merely an announcement or certification. Therefore, the correct classification is AR with high confidence. FY 2023
2024-04-25 Chinese
董事会审计委员会2023年度履职情况报告
Audit Report / Information Classification · 95% confidence The document is titled as a report from the Board Audit Committee for the year 2023, detailing their duties, meetings, and evaluations related to the company's financial reports and audit work. It includes descriptions of the committee's oversight of financial reporting, external audit evaluations, and internal control assessments. The document is not a full annual report or financial statement but a specific report on the audit committee's activities and responsibilities for the year. This fits the definition of an Audit Report / Information (AR), which includes standalone audit reports and related information. The document length is 2360 characters, which is short but contains substantive content about audit committee activities rather than just an announcement or certification. Therefore, it should be classified as AR with high confidence. FY 2023
2024-04-25 Chinese
非经营性资金占用及其他关联资金往来情况汇总表的专项审核报告
Audit Report / Information Classification · 95% confidence The document is titled as a "专项审核报告" (special audit report) related to the 2023年度非经营性资金占用及其他关联资金往来情况汇总表 (2023 non-operating fund occupation and other related party fund transactions summary). It is issued by a certified public accounting firm and references auditing standards and regulatory guidelines from Chinese securities regulators. The document includes an audit opinion on a specific financial summary table prepared by management, not the full annual financial statements. It explicitly states it is a special audit report on a particular aspect of the company's financials, not the full annual report or interim report. The document length is 6666 characters, which is substantial and contains detailed audit content. This fits the definition of an Audit Report / Information (AR) as it is a standalone audit report on a specific financial matter, separate from the full annual report (10-K).
2024-04-25 Chinese

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.